| BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma |
Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response in the first eight patients evaluated Results equate to an objective response rate (CRs and PRs) of 63% Data from an earlier cutoff date in February are included in an abstract published today by the European Hematology Association (EHA) 2025 conference LUND, SE / ACCESS Newswire / May 14, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces latest updated data from the ongoing Phase 2a study of BI-1206 in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL). Additionally today, an abstract containing data from an earlier February cutoff date has been published by the European Hematology Association (EHA) as part of its 2025 congress due to take place June 12-15 in Milan, Italy. |
accessnewswire.com |
2025-05-14 13:40:00 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89% |
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-09 15:00:59 |
Czytaj oryginał (ang.) |
| IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial |
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone. The trial was not statistically pow. |
businesswire.com |
2025-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| AstraZeneca's Imfinzi delays bladder cancer return in high-risk patients |
AstraZeneca PLC (LSE:AZN) has reported encouraging results from a late-stage trial of its cancer immunotherapy Imfinzi, which significantly extended the time patients with early-stage bladder cancer lived without their disease coming back or getting worse. The data, released Friday, come from the company's phase III POTOMAC trial and mark a potential breakthrough for patients with high-risk non-muscle-invasive bladder cancer, a form of the disease that accounts for the majority of bladder cancer diagnoses and has a stubborn tendency to return. |
proactiveinvestors.co.uk |
2025-05-09 06:51:18 |
Czytaj oryginał (ang.) |
| Tempus AI Stock: Time to Double Down or Cut and Run? |
Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance. |
marketbeat.com |
2025-05-08 11:46:53 |
Czytaj oryginał (ang.) |
| AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief |
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) on the back of an appointment by Donald Trump and his health secretary Robert F Kennedy Jnr of a key position at the US drug regulator. Vinay Prasad, a vaccine sceptic like Kennedy, has been made head of the US Food and Drug Administration's Center for Biologics Evaluation and Research. |
proactiveinvestors.co.uk |
2025-05-07 09:53:47 |
Czytaj oryginał (ang.) |
| AZN or ARGX: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-05-06 16:46:05 |
Czytaj oryginał (ang.) |
| AstraZeneca's Breztri meets main goals of late-stage asthma trials |
Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma. |
reuters.com |
2025-05-02 06:20:46 |
Czytaj oryginał (ang.) |
| AstraZeneca has plenty coming down the pipeline to appease the bears |
AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company's longer-term potential. The bank retains its 'buy' rating with a price target of 14,200p, offering more than 30% upside from the current share price of around 10,600p. |
proactiveinvestors.co.uk |
2025-04-30 12:23:47 |
Czytaj oryginał (ang.) |
| AstraZeneca has built resilient supply chains in U.S., China: CEO |
AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets. |
youtube.com |
2025-04-29 16:08:23 |
Czytaj oryginał (ang.) |
| Pharma firms maastraz |
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector. |
youtube.com |
2025-04-29 16:06:03 |
Czytaj oryginał (ang.) |
| AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript |
AstraZeneca PLC (NASDAQ:AZN ) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - EVP, Oncology Business Unit Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Unit Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - CEO, Alexion Iskra Reic - EVP, International Conference Call Participants Sarita Kapila - Morgan Stanley James Gordon - JPMorgan Rajan Sharma - Goldman Sachs? Sachin Jain - Bank of America Steve Scala - Cowen Mattias Haggblom - Handelsbanken Matthew Weston - UBS Justin Smith - Bernstein Seamus Fernandez - Guggenheim Simon Baker - Redburn Rajesh Kumar - HSBC Luisa Hector - Berenberg Peter Verdult - BNP Operator Good morning to those joining from the UK and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia. |
seekingalpha.com |
2025-04-29 15:46:07 |
Czytaj oryginał (ang.) |
| AstraZeneca CEO talks tariffs, first quarter earnings |
AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted its commitment to US investments amid tariff concerns. |
youtube.com |
2025-04-29 15:35:43 |
Czytaj oryginał (ang.) |
| AstraZeneca shares claw their way back into green after revenue miss |
After an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the results. At face value, the update looked reassuring. |
proactiveinvestors.co.uk |
2025-04-29 15:17:58 |
Czytaj oryginał (ang.) |
| Here's Why Astrazeneca (AZN) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-29 14:40:25 |
Czytaj oryginał (ang.) |
| Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-04-29 14:36:10 |
Czytaj oryginał (ang.) |
| AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs |
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments. |
zacks.com |
2025-04-29 14:15:46 |
Czytaj oryginał (ang.) |
| AstraZeneca shows its strength despite sales miss |
AstraZeneca PLC (LSE:AZN) has once again shown why it sits at the top table of global pharmaceuticals. Although first-quarter sales missed City forecasts by a whisker, profits came in well ahead of expectations, keeping the company firmly on track for a year of solid growth. |
proactiveinvestors.co.uk |
2025-04-29 14:02:34 |
Czytaj oryginał (ang.) |
| AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors |
The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the European Union, provided they are in line with rates for other sectors. |
reuters.com |
2025-04-29 09:16:57 |
Czytaj oryginał (ang.) |
| BioInvent International AB: Year-End Report January 1 - December 31, 2024 |
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets. |
accessnewswire.com |
2025-02-27 04:30:00 |
Czytaj oryginał (ang.) |
| AstraZeneca gets £2bn boost from breast cancer drug readout |
AstraZeneca PLC (LSE:AZN) has seen £2 billion added to its market value after reporting positive results from a breast cancer drug trial. The experimental treatment, camizestrant, improved patient survival without the disease worsening, according to an interim analysis. |
proactiveinvestors.co.uk |
2025-02-26 10:51:54 |
Czytaj oryginał (ang.) |
| Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial |
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing. |
businesswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| AstraZeneca therapy improves survival in late-stage breast cancer trial |
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage trial. |
reuters.com |
2025-02-26 04:19:01 |
Czytaj oryginał (ang.) |
| Final Trades: Starbucks, Astrazeneca, Western Union and the IYR |
The Investment Committee give you their top stocks to watch for the second half. |
youtube.com |
2025-02-25 15:20:55 |
Czytaj oryginał (ang.) |
| AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion |
Investors can contact the law firm at no cost to learn more about recovering their losses |
globenewswire.com |
2025-02-24 17:30:00 |
Czytaj oryginał (ang.) |
| Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing |
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications. |
prnewswire.com |
2025-02-24 06:00:00 |
Czytaj oryginał (ang.) |
| 3 Magnificent Growth Stocks to Buy Right Now |
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value. |
fool.com |
2025-02-22 07:47:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131420&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-21 18:15:00 |
Czytaj oryginał (ang.) |
| AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN |
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. |
globenewswire.com |
2025-02-21 15:43:00 |
Czytaj oryginał (ang.) |
| AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131284&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-21 12:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming Deadlines - AZN |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-21 12:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131175&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-21 09:30:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER AZN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts AstraZeneca PLC Investors to Participate in the Class Action Lawsuit |
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-02-21 09:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky |
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. |
prnewswire.com |
2025-02-21 07:45:00 |
Czytaj oryginał (ang.) |
| AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm |
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
prnewswire.com |
2025-02-21 02:35:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131097&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-20 22:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131058&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-20 19:15:00 |
Czytaj oryginał (ang.) |
| AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131030&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-20 18:00:00 |
Czytaj oryginał (ang.) |
| Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN |
LOS ANGELES , Feb. 20, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025. |
prnewswire.com |
2025-02-20 17:56:00 |
Czytaj oryginał (ang.) |